From 1982 through 1996, 547 untreated advanced ovarian cancer patients were entered onto Gruppo Oncologico Nord-Ovest (GONO) consecutive randomized trials including cisplatin-based chemotherapy. End points of analysis included the influence of age on prognosis, toxicity, clinical/surgical response rates, progression-free survival and survival. Of the entire study group, 116 patients were 65 years of age or older at diagnosis. WHO main toxicity (any grade) consisted of: emesis (93% of patients), myelotoxicity (leukopenia in 52%, anemia in 51% and thrombocytopenia in 17% of patients), nephrotoxicity in 13% of patients and neurotoxicity in 10% of patients. No significant difference in toxicity was evident between patients > or = or <65 years. Refusal of CT and early (< or =2 courses) interruption of CT due to toxicity were more frequent in elderly patients (3.4 vs. 1.4%; 3.4 vs. 0.7%, respectively). After a median follow-up of 71 months no difference was observed in survival and progression-free survival between younger and older patients. Cox multiple regression analysis of the entire study population demonstrated that age >65 years per se was not a negative prognostic factor.
|Data di pubblicazione:||2001|
|Titolo:||Advanced Ovarian Cancer in the elderly: results of Consecutive trials with Cisplatin based chemotherapy.|
|Autore/i:||S. Chiara; R. Lionetto; M. Vincenti; M. Bruzzone; M.T. Nobile; A. Gadducci; F. Carnino; R. Rosso; P.F. Conte|
|Codice identificativo ISI:||WOS:000166559800003|
|Codice identificativo Scopus:||2-s2.0-0035148184|
|Citazione:||Advanced Ovarian Cancer in the elderly: results of Consecutive trials with Cisplatin based chemotherapy / S. Chiara; R. Lionetto; M. Vincenti; M. Bruzzone; M.T. Nobile; A. Gadducci; F. Carnino; R. Rosso; P.F. Conte. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - STAMPA. - 37(2001), pp. 27-34.|
|Tipologia||Articolo su rivista|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris